Luye Pharma will have exclusive rights to develop and commercialize Zepsyre® for Small Cell Lung Cancer and al...
From August 28 to 31, the 17th National Congress of Psychiatry (CSP2019) of the Chinese Medical Association wa...
Luye Pharma Group (02186 HK) released its financial results for the first half of 2019 on August 28 The resul...
Luye Pharma grants AstraZeneca exclusive rights to promote natural lipid-regulating drug Xuezhikang Capsules i...
Australia s most attractive employers announced; Healthe Care ranked 12th alongside Qantas, Apple and Virgin
The pivotal study for Rivastigamine Multi-Day Transdermal Patch (Rivastigamine MD) has been completed in Germa...
TOP